Amryt Pharma is a biopharmaceutical company focused on commercializing and developing therapeutics to treat patients suffering from serious and life-threatening rare disease. Co.'s two commercial products, lomitapide for the treatment of homozygous familial hypercholesterolemia (HoFH), and metreleptin for the treatment of generalized lipodystrophy (GL) and partial lipodystrophy. Lomitapide is an oral therapy as an adjunct to a low-fat diet and other lipid-lowering treatments for adults with HoFH. Metreleptin for injection is under the trade name Myalept as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired GL. The AMYT stock yearly return is shown above.
The yearly return on the AMYT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AMYT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|